Trial Profile
A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 30 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 May 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 27 May 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.